Abstract:Background and aims: Peroxisome proliferator-activated receptor alpha (PPARa) regulates expression of multiple genes involving lipid metabolism, bile acids (BA) homeostasis, and shows protective effects against inflammation and apoptosis.Progressive diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) result in intrahepatic retention of toxic BA that may lead to liver dysfunction and failure.Small non-coding RNA molecules (miRNAs) regulate gene expression, and miR-155 was associated with silencing of PPARa.Since PPARa activation decreases inflammation and fibrosis we evaluated PPARa and miR-155 expressions in cholestatic livers.We have also analyzed the regulatory effect of miR-155 on PPARa expression in vitro.Method: Liver samples were taken from biopsies at early stages (F1-F2) of PBC (n = 12) or from explanted livers in patients with cirrhotic PBC (n = 11) and PSC (n = 17).The functional role of miR-155 was characterized in vitro in hepatocytes (HepG2) and primary cholangiocytes (NHC) where overexpression of miR-155 was induced by mirVana miRNA Mimic.miR-155 expression levels were evaluated after treatment with lipopolysaccharide (LPS), glycodeoxycholic acid (GCDCA), lithocholic acid (LCA) or ursodeoxycholic acid (UDCA).Results: When compared to controls hepatic PPARa mRNA and protein levels were reduced in cirrhotic PBC (both 50% reduction, P = 0.01), but not in PSC livers.In PBC livers this phenomenon was accompanied with induction of miR-155 (3.7-fold increase, P = 0.004 vs. control).Experimental overexpression of miR-155 in HepG2 led to the inhibition of PPARa (50% reduction, P = 0.02).LPS stimulated miR-155 expression in HepG2 (over 40-fold increase, p = 0.009), whereas the treatment with GCDCA or LCA enhanced the expression of miR-155 in NHC (2-fold p < 0.05, or 2.4 fold p < 0.05, respectively).UDCA suppressed the basal expression of miR-155 in NHC (20% reduction, p = 0.02 vs. control) as well as the LPS-induced miR-155 in HepG2 ( p = 0.009 vs LPS). Conclusion:We showed that PPARa is substantially reduced in PBC livers, and the observed concomitant overexpression of miR-155 induced either by inflammation or bile acids may be accountable for this suppression.Inhibition of miR-155 may be a potential novel therapeutic target in PBC.

P53-Mediated Regulation of Bile Acid Disposition Attenuates Cholic Acid-Induced Cholestasis in Mice

P53 Attenuates Acetaminophen-Induced Hepatotoxicity by Regulating Drug-Metabolizing Enzymes and Transporter Expression

P53 Deficiency Affects Cholesterol Esterification to Exacerbate Hepatocarcinogenesis.

p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl4

Silencing of Functional P53 Attenuates NAFLD by Promoting HMGB1-related Autophagy Induction

Cholesterol esterification and p53-mediated tumor suppression

p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis

p53 suppresses lipid droplet–fueled tumorigenesis through phosphatidylcholine

Cholangiocytes-Specific Deletion of Sphingosine-1-phospholipid Receptor 1 Attenuate Cholestasis Induced Liver Injury and Fibrosis

Suppression of P53 Potentiates Chemosensitivity in Nutrient-Deprived Cholangiocarcinoma Cells Via Inhibition of Autophagy

Pterostilbene Alleviates Cholestasis by Promoting SIRT1 Activity in Hepatocytes and Macrophages

Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy.

p53 promotes peroxisomal fatty acid beta-oxidation to repress purine biosynthesis and mediate tumor suppression

p53 promotes peroxisomal fatty acid β-oxidation to repress purine biosynthesis and mediate tumor suppression

p53 promotes peroxisomal fatty acid -oxidation to repress purine biosynthesis and mediate tumor suppression

Rb and p53 Liver Functions Are Essential for Xenobiotic Metabolism and Tumor Suppression

Protective Role of P53 in Acetaminophen Hepatotoxicity

Metabolomic Analysis Reveals the Therapeutic Effects of MBT1805, a Novel Pan-Peroxisome Proliferator-Activated Receptor Agonist, on Α-Naphthylisothiocyanate-induced Cholestasis in Mice

Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex

Quercetin Potentiates Doxorubicin Mediated Antitumor Effects Against Liver Cancer Through P53/Bcl-Xl

The Role of Sphingosine 1‐phosphate Receptor 2 in Bile‐acid–induced Cholangiocyte Proliferation and Cholestasis‐induced Liver Injury in Mice